BDTX BDTX
Company Profile ↓Company Overview
BDTX (BDTX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 19.9%, reflecting efficient use of shareholder capital.
Trades at an undemanding P/E of 4.6.
Maintains a net profit margin of 31.9%.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -36.75% |
| 6 Months: | -28.97% |
| 3 Months: | -37.63% |
| 1 Month: | -13.94% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.67 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 31.9%.
CONS
- Trading 63.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -1.60M | -1.91M | -2.34M | -3.05M | -3.84M | -7.00M | -8.15M | -10.34M | -12.88M | -15.03M | -18.48M | -23.18M | -30.71M | -34.72M | -35.36M | -25.68M | -23.17M | -22.12M | -21.56M | -20.03M | -24.01M | -20.25M | -22.13M | -18.13M | 54.53M | -13.42M | -10.98M | -11.26M |
| Net Income | -1.59M | -1.91M | -2.36M | -3.07M | -3.83M | -12.29M | -9.27M | -9.88M | -12.14M | -14.57M | -17.91M | -22.63M | -30.30M | -34.35M | -35.08M | -25.51M | -22.93M | -21.65M | -20.88M | -19.15M | -23.01M | -18.23M | -19.91M | -15.56M | 56.54M | -10.56M | -8.50M | -9.04M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.51 | -0.41 | -0.50 | - | -0.84 | -0.95 | -0.97 | -0.70 | -0.63 | -0.60 | -0.57 | -0.52 | -0.45 | -0.35 | -0.36 | -0.28 | 0.98 | -0.19 | -0.15 | -0.16 |
| R&D Expense | - | - | - | - | 3.01M | 5.65M | 5.63M | - | 7.35M | 10.17M | 12.93M | - | 22.82M | 26.72M | 27.63M | 17.79M | 16.20M | 15.85M | 14.75M | 13.15M | 16.15M | 13.54M | 12.56M | 12.91M | 10.51M | 9.32M | 7.44M | 7.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | - | - | - | 0 | 70.00M |
| Operating Income | -8.90M | -29.33M | -69.57M | -126.87M | -92.83M | -86.46M | -78.78M | 12.52M |
| Net Income | -8.93M | -35.26M | -67.25M | -125.60M | -91.17M | -82.44M | -69.68M | 22.37M |
| Diluted EPS | - | - | -2.05 | -3.47 | -2.52 | -1.88 | -1.27 | 0.39 |
| R&D Expense | 6.95M | 21.75M | 48.21M | 96.83M | 64.44M | 59.35M | 51.31M | 33.56M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 51.83M | 158.29M | 329.67M | 247.68M | 156.25M | 158.57M | 122.64M | 143.01M |
| Total Equity | -6.67M | -15.54M | -47.16M | 307.76M | 195.90M | 115.69M | 116.74M | 83.28M | 112.21M |
| Cash & Equivalents | - | 51.66M | 154.67M | 34.60M | 65.80M | 34.31M | 56.22M | 36.44M | 20.99M |
| Total Liabilities | - | 6.60M | 4.88M | 21.91M | 51.78M | 40.56M | 41.83M | 39.35M | 30.80M |
| Current Liabilities | - | 2.58M | 4.86M | 14.22M | 23.64M | 15.26M | 19.65M | 20.57M | 15.73M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.45M | -24.67M | -52.15M | -100.15M | -85.08M | -66.72M | -62.30M | 29.61M |
| Investing Cash Flow | -76.00K | -21.00K | -281.69M | 130.61M | 53.37M | 16.35M | 16.97M | -44.91M |
| Financing Cash Flow | 52.31M | 127.76M | 214.94M | 729.00K | 177.00K | 71.93M | 25.55M | -146.00K |
| Capital Expenditure | -76.00K | -21.00K | -142.00K | -2.71M | -192.00K | -33.00K | -0 | - |
| Free Cash Flow | -8.53M | -24.70M | -52.29M | -102.86M | -85.27M | -66.75M | -62.30M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | 17.9% |
| Net Margin % | - | - | - | - | - | - | - | 32.0% |
| ROE % | 57.5% | 74.8% | -21.9% | -64.1% | -78.8% | -70.6% | -83.7% | 19.9% |
| ROCE % | -18.1% | -19.1% | -22.1% | -56.6% | -65.8% | -62.2% | -77.2% | 9.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BDTX
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOTDBCWVlDemh5NDl4TDJMbk1FMmJaRzIzTGFxeExKVll4Nlp2TXl6Szl5VktHdTIwV0VQQno3bURFR0xoWWgxb3FVMmc1cDR3cG51ZzdrdWJnYjJ2NmNaaVRrN2p0dXpFTnRzcmJDNURfZGE5SDlwYTFwcDBRRV9QeUIydzJ2UXhZMmxHNW…
BDTX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9GMEdaYTNCSEhJSVNxeElRSlBFNG11MUoycGNoSDRwMlRwUmZtOG44NkhsWVZDbUlmVzRuMFJrSjkyOTVQVzZuUVg0QVVDd21TQUliWWk2RkR1aDQtT1F0TXZzb1Y3UUdZMVUzYjB0UEVOektTVU1ZYWdn?oc=5" target="_blank">BDT…
Lung cancer drug data from Black Diamond gets ASCO oral slot - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPQjNrbVVHZjZjM2hoVFhLOW5ReXJRTzI1UXZkOTNkNUZSX3lwMEZrVHRBUFY2M292bGhIdU4xRmRKY1FOaXpvUUNCWFZpN0NZdTJmVGcyR1FzS3NTel9lNWpjazhkZ2R0RDdPX3J0R1FFTXpOYUM5bkJfd0lEa0hsQzR2Z051aXlWRUhnMW…
Stifel reiterates Black Diamond Therapeutics stock rating at Buy - Investing.com
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQa2FaazZOcldJMnFvWU1pWEgwM3ZWWUNHc1JRT0xSWlhaVTZIbWx0amVkUEtnUVZLaHZEZVlULWpqN2RSM3M4MjY3RVItSWd2cGExU29XWXc2bkV3aW5WejAyWjlLNndWZ3BlVnRFVFltNjNPek5GYzhHZzdZQm11M2hHTTFNUzdaR204Nn…
BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNVHZMMGMxQ0lBdVdUV21SZXk1SWh1T2dnUnQzVmtuY3Q0ZTJ1bVNzZEFYRnhNSWlMYlZBT1J2WjFVVFhQMU14Q0gwSVdpblk5V3FDTGJ3emRfSjl2RWJyaGczQTFSbHNjeXZ5R1VPaTI2SXpXdHQ4V09uOC15NkVmQU9tQThRbFFNalZjLT…
Black Diamond Therapeutics, Inc. Common Stock (BDTX) Stock Price Today: $1.70 - Gotrade
<a href="https://news.google.com/rss/articles/CBMiV0FVX3lxTE14QzhKemtkU3A2SFR0SVkzbEdVRDFWQ09xcTRGQTFIVVExdWFiam5aa2N1MW1UTDUtSTNNMzZDX2lPMVhRaHVVNlowUHo3cWJGV3I3dW5JTQ?oc=5" target="_blank">Black Diamond Therapeutics, Inc. Common Stock (BD…
BDTX — Frequently Asked Questions
What is the current share price of BDTX?
As of 2026-08-05 17:25 PDT, BDTX trades at $1.79 on NASDAQ/NYSE. Its 52-week range is $1.61 to $4.87.
What is the P/E ratio of BDTX?
BDTX trades at a trailing price-to-earnings (P/E) ratio of 4.59.
What is the return on equity (ROE) of BDTX?
BDTX has a return on equity (ROE) of 19.93%. Its return on capital employed (ROCE) is 9.84%.
Is BDTX a good stock to buy?
This page provides a data-driven analysis of BDTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.